Today: 30 April 2026
Invesco QQQ Sees Fresh Wealth-Manager Interest, but Old Filings Blur the Signal
9 March 2026
2 mins read

Invesco QQQ Sees Fresh Wealth-Manager Interest, but Old Filings Blur the Signal

NEW YORK, March 9, 2026, 10:14 EDT

  • Fort Sheridan Advisors and CreativeOne Wealth have both made notable moves, ramping up their late-2025 QQQ bets, according to recent reports.
  • Fort Sheridan’s Dec. 31 filing revealed a reduced QQQ position, underscoring how Form 13F filings trail actual portfolio moves.
  • QQQ slipped to around $593 early Monday, off roughly 1.1%. SPY and XLK lost ground as well.

New filings out March 8 and 9 have brought attention back to Invesco QQQ, the ETF tied to the Nasdaq-100, after bigger allocations showed up in the portfolios of two U.S. wealth managers. But the numbers refer to holdings expected late 2025, not current stakes.

That’s a key question for investors, who are weighing whether concentrated growth trades have more room to run as the Middle East conflict, rising oil prices, and uncertainty over U.S. rate cuts rattle equities. Early Monday in New York, QQQ traded near $593, down about 1.1%—tracking close to the broader SPY, but lagging the tech-focused XLK.

On March 9, MarketBeat noted that Fort Sheridan Advisors, based in Highland Park, Illinois, picked up another 1,773 QQQ shares during the third quarter, bumping its total to 8,466 shares—worth roughly $5.08 million. The day before, a separate report highlighted CreativeOne Wealth’s 15.9% boost to its QQQ holdings during that same period, now totaling 110,146 shares valued at $66.13 million.

Big U.S. money managers are required to submit Form 13F to the SEC within 45 days after each quarter wraps up. The filing sometimes highlights broad portfolio trends, but treating it like a real-time trade tip is a mistake—it’s a lagging snapshot.

Fort Sheridan offers a case in point. As of September 30, 2025, it reported holding 8,466 QQQ shares. That number dropped to 7,220 shares by year-end, according to a December 31 filing submitted February 10 — putting the stake’s value at roughly $4.44 million.

Still, QQQ stands out as a straightforward route for advisers looking to access U.S. mega-cap growth at scale. According to Invesco, the fund tracks the 100 biggest non-financial names on Nasdaq, carries a 0.18% expense ratio, and ranked as the second-most traded ETF in the U.S. at Dec. 31, 2025.

What if energy prices stay up, inflation doesn’t cool, and growth loses steam? That’s the stagflation scenario investors dread. “A stagflationary shock was not part of the plan,” ING’s global markets chief Chris Turner said Monday. Lale Akoner, strategist at eToro, put it this way: if inflation proves stubborn, “multiples, not earnings, are the weak link.” Reuters

Peter Oppenheimer, Goldman Sachs’ chief global equities strategist, flagged “correction risks as high” for global stocks in a note last week. Still, he doesn’t anticipate a major bear market—he thinks any dip might open up buying chances. Oppenheimer also called for wider diversification: regions, sectors, factors. Reuters

The latest QQQ filings give investors a partial glimpse. Advisers stayed with the Nasdaq-100 play through the third quarter, the reports show. But they’re nearly silent on whether that conviction held up during February’s turbulence or March’s spike in oil—investors probably won’t get a more complete picture until the next 13F drop in mid-May.

Stock Market Today

  • Jim Cramer's Top 10 Market Watch Items Including Hyperscalers and Eli Lilly
    April 30, 2026, 9:39 AM EDT. Jim Cramer's top 10 stock market items for Thursday April 30 spotlight hyperscalers Alphabet, Amazon, Microsoft, and Meta. Alphabet's shares surged 8% on AI spending and cloud growth. Amazon's AWS cloud expanded 28%, with shares up 3.5%. Microsoft's cloud grew 40%, but stock dipped over 1%. Meta's shares fell 8.5% after a dip in daily users and increased capital expenditures. Eli Lilly posted strong earnings, shares up 6%. Cardinal Health's quarter was weaker than expected, shares down 1%. Overall, markets look set for a positive open amid softer oil prices and yields. Federal Reserve Chair Jerome Powell plans to stay on as governor after his term ends. Anthropic is reportedly raising funds at a $900 billion valuation.

Latest article

FuelCell Energy Stock Jumps as AI Power Boom Puts FCEL Back in Play

FuelCell Energy Stock Jumps as AI Power Boom Puts FCEL Back in Play

30 April 2026
FuelCell Energy shares jumped 37% Wednesday, trading near a one-year high at $13.64 premarket Thursday, as investors bet on fuel-cell demand for AI data centers. Rival Bloom Energy reported Q1 revenue up 130% to $751.1 million and will supply up to 2.45 GW of fuel cells to Oracle’s Project Jupiter. FuelCell’s January-quarter revenue rose 61% to $30.5 million but it posted a net loss of $26.1 million.
America’s Credit Split Is Getting Worse: TransUnion Data Shows Who Is Being Squeezed

America’s Credit Split Is Getting Worse: TransUnion Data Shows Who Is Being Squeezed

30 April 2026
TransUnion reported a sharper split in U.S. consumer credit, with 15 million more borrowers in the super-prime tier since 2019, while near-prime and subprime borrowers face rising debt-to-income ratios. Bankcard balances hit $1.12 trillion in Q1, and personal loan originations reached 7.6 million in Q4, both up from a year earlier. Mortgage delinquencies of 60 days or more rose to 1.57%.
PennyMac Investor Probe Deepens After 33% Stock Plunge: What PFSI Holders Need To Know

PennyMac Investor Probe Deepens After 33% Stock Plunge: What PFSI Holders Need To Know

30 April 2026
Rosen Law Firm said it is preparing a class action for PennyMac Financial Services investors after the company’s January earnings disclosure triggered a 33.3% one-day stock drop. Schall Law Firm launched a separate investigation into possible false or misleading statements. PennyMac’s servicing segment pretax income fell to $37.3 million from $157.4 million in the prior quarter. The company reports first-quarter results May 5.
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now
Previous Story

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds
Next Story

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Go toTop